A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

Alcon Research

Overview

To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Glaucoma, Angle-Closure Ocular Hypertension

Interventions

Travoprost (0.004%)DRUG

Latanoprost (0.005%)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Adult patients of any race and either sex with chronic angle-closure glaucoma.

Locations (2)

Asia

Fort Worth, Texas, United States

Australia

Sydney, Australia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.